NCT01470027View on ClinicalTrials.gov

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Parkinson Disease
Interventions
DRUG

N-acetylcysteine

900mg NAC effervescent tablets

DRUG

Placebo

effervescent tablets

Trial Locations (1)

10021

Weill Cornell Medical College, New York

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT01470027 - N-Acetylcysteine for Neuroprotection in Parkinson's Disease | Biotech Hunter | Biotech Hunter